Repeat Stereotactic Radiosurgery for Recurred Metastatic Brain Tumors
- Author:
In Young KIM
1
;
Shin JUNG
;
Tae Young JUNG
;
Kyung Sub MOON
;
Woo Youl JANG
;
Jae Young PARK
;
Tae Wook SONG
;
Sa Hoe LIM
Author Information
- Publication Type:Original Article
- Keywords: Metastasis; Gamma knife radiosurgery; Radiation therapy; Recurrence; Stereotactic radiosurgery
- MeSH: Brain Neoplasms; Brain; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cause of Death; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Magnetic Resonance Imaging; Male; Mortality; Neoplasm Metastasis; Prescriptions; Radiosurgery; Recurrence; Small Cell Lung Carcinoma; Tumor Burden
- From:Journal of Korean Neurosurgical Society 2018;61(5):633-639
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: We investigated the outcomes of repeat stereotactic radiosurgery (SRS) for metastatic brain tumors that locally recurred despite previous SRS, focusing on the tumor control.METHODS: A total of 114 patients with 176 locally recurring metastatic brain tumors underwent repeat SRS after previous SRS. The mean age was 59.4 years (range, 33 to 85), and there were 68 male and 46 female patients. The primary cancer types were non-small cell lung cancer (n=67), small cell lung cancer (n=12), gastrointestinal tract cancer (n=15), breast cancer (n=10), and others (n=10). The number of patients with a single recurring metastasis was 95 (79.8%), and another 19 had multiple recurrences. At the time of the repeat SRS, the mean volume of the locally recurring tumors was 5.94 mL (range, 0.42 to 29.94). We prescribed a mean margin dose of 17.04 Gy (range, 12 to 24) to the isodose line at the tumor border primarily using a 50% isodose line.RESULTS: After the repeat SRS, we obtained clinical and magnetic resonance imaging follow-up data for 84 patients (73.7%) with a total of 108 tumors. The tumor control rate was 53.5% (58 of the 108), and the median and mean progression-free survival (PFS) periods were 246 and 383 days, respectively. The prognostic factors that were significantly related to better tumor control were prescription radiation dose of 16 Gy (p=0.000) and tumor volume less than both 4 mL (p=0.001) and 10 mL at the repeat SRS (p=0.008). The overall survival (OS) periods for all 114 patients after repeat SRS varied from 1 to 56 months, and median and mean OS periods were 229 and 404 days after the repeat SRS, respectively. The main cause of death was systemic problems including pulmonary dysfunction (n=58, 51%), and the identified direct or suspected brain-related death rate was around 20%.CONCLUSION: The tumor control following repeat SRS for locally recurring metastatic brain tumors after a previous SRS is relatively lower than that for primary SRS. However, both low tumor volume and high prescription radiation dose were significantly related to the tumor control following repeat SRS for these tumors after previous SRS, which is a general understanding of primary SRS for metastatic brain tumors.
